Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
PR Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤$884.4 million cash, equivalents and securities expected to fund operations into 2030
- ➤FDA aligned on final ENABLE-2 Phase 3 design for relcobatinib
- ➤ENABLE-2 initiation remains on track before year-end 2026
- ➤Q3 net loss $27.7 million versus $20.1 million year over year
- ➤Q3 R&D expenses $28.0 million versus $18.2 million year over year
Expert Statements
Rick Fair, Chief Executive Officer of Enliven Therapeutics
“This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial”
Rick Fair, Chief Executive Officer of Enliven Therapeutics
“The compelling ENABLE data presented at EHA in June generated strong engagement across the medical community, and we are encouraged by the enthusiasm from physicians and investigators as we prepare to initiate ENABLE-2.”
Rick Fair, Chief Executive Officer of Enliven Therapeutics
“As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program.”
Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update PR Newswire
Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial
Get started
Create a free account to read the full story.